Phys 1992, 24:98386. 41. McGinn CJ, Lawrence TS: Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001, 11:27080. 42. Wurschmidt F, Dahle J, Petersen C, Wenzel C, Kretschmer M, Bastian C: Reirradiation of recurrent breast cancer with and without concurrent chemotherapy. Radiat Oncol 2008, three:28. 43. Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, Masters GA, Fleming GF, Heimann R: Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: outcomes from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 2005, 61:1045053. 44. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002, 20:3906927. 45. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation with the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998, 58:5686689. 46. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW: Simultaneous inhibition on the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived development factors suppresses tumor development and enhances tumor radiation response. Cancer Res 2002, 62:1702706. 47. Wondrak GT, Jacobson MK, Jacobson EL: Endogenous UVA-photosensitizers: mediators of skin photodamage and novel targets for skin photoprotection. Photochem Photobiol Sci 2006, 5:21537. 48. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M: No evidence for elevated skin cancer threat in psoriasis sufferers treated with broadband or narrowband UVB phototherapy: a very first retrospective study. Acta Derm Venereol 2004, 84:37074. 49. Hirakawa S, Fujii S, Kajiya K, Yano K, Detmar M: Vascular endothelial growth aspect promotes sensitivity to ultraviolet B-induced cutaneous photodamage. Blood 2005, 105:2392399. 50. Sasaki K, Tsuno NH, Sunami E, Kawai K, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, Murono K, Tada N, et al: Radiosensitization of human breast cancer cells to ultraviolet light by 5-fluorouracil. Oncology letters 2011, 2:47176. 51. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR: ZD6474, a potent inhibitor of vascular endothelial growthSarkar et al. Molecular Cancer 2013, 12:122 http://www.molecular-cancer/content/12/1/Page 18 of52.53. 54.55.56.57.58. 59.60.61.62. 63. 64.65.66.67.68.69.70.71.72.73.aspect signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004, 10:8587593. Allan LA, Fried M: p53-dependent apoptosis or growth arrest induced by distinctive types of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene 1999, 18:5403412.Odevixibat Wu Y, Xing D, Chen WR, Wang X: Bid isn’t necessary for Bax translocation through UV-induced apoptosis.Datopotamab Cellular signalling 2007, 19:2468478.PMID:26895888 Sarkar S, Mandal M: Development element receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and therapy outcomes of breast cancer. Breast Cancer Res 2009, three:470. Geyer RK, Nagasawa H, Tiny JB, Maki CG: Function and regulation of p53 throughout an ultraviolet radiation-induced G1 cell cycle arrest. Cell development differ 2000, 11:14956. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M: ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol 2011, 226:37584. Bortner DM, Rosenberg MP: Induction of mammary gland hyperp.
Nucleoside Analogues nucleoside-analogue.com
Just another WordPress site
